| Description |
COX2-IN-1 is a selective and inducible COX2 inhibitor with an IC50 of 0.24 μM. COX2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
|
| Related Catalog |
|
| Target |
COX-2:240 nM (IC50)
|
| In Vitro |
COX2-IN-1 shows no COX-1 inhibition even at 100μM[1].
|
| In Vivo |
COX2-IN-1 has oral ED50 values of 0.030 and 0.47mg/kg on adjuvant-induced arthritis and collagen-induced arthritis, respectively, and an ED30 value of 7.4mg/kg in the yeast-induced hyperalgesia (Randall-Selitto) assay. COX2-IN-1 shows good analgesic activity and no ulcerogenicity[1].
|
| Kinase Assay |
hCOX1 or hCOX2 is preincubated with COX2-IN-1 in 0.1 M Tris-HCl buffer containing 2 μM hematin and 5 mM L-tryptophan at 30 °C for 5 min, followed by a 5 min incubation with arachidonic acid. The enzyme reaction is stopped by the addition of 1 N HCl. The PGE2 formed is extracted with EtOAc and measured by RIA[1].
|
| Animal Admin |
Rats: Ten male Sprague Dawley rats are used per group. A suspension of 0.5% brewer's yeast in 0.5% methyl cellulose is injected into the right hind paw. The pain threshold us determined 3h after yeast injection. COX2-IN-1 is given orally 2 h after yeast injection. The pain threshold in the treated rats are compared with that in the control rats[1].
|
| References |
[1]. Tsuji K, et al. Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull (1997), 45(6), 987-995.
|
